DGX
NEUTRAL
$196.27
Live
Quest Diagnostics Incorporated · NYSE
Target $222.56
(+13.4%)
$164.65
52W Range
$213.5
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 26, 2026
Market cap
$21.73B
P/E
21.69
ROE
14.5%
Profit margin
9.1%
Debt/Equity
0.83
Dividend yield
1.75%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
DGX exhibits stable fundamental health with a Piotroski F-Score of 6/9 and a sustainable dividend payout ratio of 36.02%. While the company shows consistent earnings growth (15.5% YoY) and a long track record of beating estimates, it is currently caught between a conservative Graham Number ($115.21) and a growth-based Intrinsic Value ($266.98). The bullish fundamental outlook is heavily offset by a 0/100 technical trend and bearish insider sentiment, with 10 sell transactions and zero buys in the last six months. Consequently, the stock appears fundamentally sound but lacks immediate price momentum.
Key Strengths
Consistent earnings track record with 3/4 beats in the last year and a long history of positive surprises
Strong earnings growth (15.5% YoY) outpacing revenue growth (9.2% YoY)
Sustainable dividend profile with a low payout ratio of 36.02%
Stable financial health indicated by a Piotroski F-Score of 6/9
Reasonable valuation relative to forward earnings (Forward P/E of 16.88)
Key Risks
Strongly bearish insider activity with $4.12M in sales and no insider buying
Bearish technical trend (0/100) suggesting lack of market momentum
Liquidity risk indicated by a Quick Ratio of 0.91 (below 1.0)
Significant premium over the Graham Number ($115.21), limiting defensive margin of safety
Exposure to clinical testing industry regulatory and reimbursement risks
AI Fair Value Estimate
Based on comprehensive analysis
$218.6
+11.4% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
73
Strong
60
82
88
72
65
AI Verdict
Fundamental Strength vs. Technical Weakness
Key drivers: Consistent EPS beats, Sustainable dividends, Bearish insider sentiment, Poor technical momentum
Confidence
90%
Value
60/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E (16.88) is attractive
- Trades below growth-based intrinsic value
Watchpoints
- Trades at a significant premium to Graham Number
- PEG ratio of 1.51 is slightly elevated
Future
82/100
Ref Growth rates
Positives
- Double-digit earnings growth
- Consistent quarterly surprise trend
Watchpoints
- Revenue growth is moderate (9.2%)
Past
88/100
Ref Historical trends
Positives
- Strong 5Y price change (+63.6%)
- Exceptional 25-quarter earnings beat record
Watchpoints
- Recent 1-month price stagnation
Health
72/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 6/9 (Stable)
- Manageable Debt/Equity ratio (0.83)
Watchpoints
- Quick ratio below 1.0
- Altman Z-Score not provided
Dividend
65/100
Ref Yield, Payout
Positives
- Very safe payout ratio (36.02%)
Watchpoints
- Low dividend yield (1.75%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$196.27
Analyst Target
$222.56
Upside/Downside
+13.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for DGX and closest competitors.
Updated 2026-04-24
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
DGX
Quest Diagnostics Incorporated
Primary
|
+63.6% | +42.2% | +13.6% | +8.7% | +0.3% | +0.6% |
|
HUM
Humana Inc.
Peer
|
-54.8% | -63.9% | -31.8% | -27.3% | -4.6% | +2.6% |
|
ROIV
Roivant Sciences Ltd.
Peer
|
+203.5% | +236.3% | +193.9% | +72.8% | +7.3% | +5.7% |
|
BNTX
BioNTech SE
Peer
|
-20.9% | -28.6% | -2.4% | -9.9% | -17.3% | +2.4% |
|
DXCM
DexCom, Inc.
Peer
|
-31.7% | -50.1% | -22.2% | -32.1% | -11.2% | +5.6% |
DGX
Quest Diagnostics Incorporated
Primary
5Y
+63.6%
3Y
+42.2%
1Y
+13.6%
6M
+8.7%
1M
+0.3%
1W
+0.6%
HUM
Humana Inc.
Peer
5Y
-54.8%
3Y
-63.9%
1Y
-31.8%
6M
-27.3%
1M
-4.6%
1W
+2.6%
ROI
Roivant Sciences Ltd.
Peer
5Y
+203.5%
3Y
+236.3%
1Y
+193.9%
6M
+72.8%
1M
+7.3%
1W
+5.7%
BNT
BioNTech SE
Peer
5Y
-20.9%
3Y
-28.6%
1Y
-2.4%
6M
-9.9%
1M
-17.3%
1W
+2.4%
DXC
DexCom, Inc.
Peer
5Y
-31.7%
3Y
-50.1%
1Y
-22.2%
6M
-32.1%
1M
-11.2%
1W
+5.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
21.69
Forward P/E
16.88
PEG Ratio
1.51
P/B Ratio
3.01
P/S Ratio
1.93
EV/Revenue
2.49
EV/EBITDA
12.63
Market Cap
$21.73B
Profitability
Profit margins and return metrics
Profit Margin
9.08%
Operating Margin
14.2%
Gross Margin
33.28%
ROE
14.54%
ROA
6.35%
Growth
Revenue and earnings growth rates
Revenue Growth
+9.2%
Earnings Growth
+15.5%
Q/Q Revenue Growth
+9.16%
Q/Q Earnings Growth
+14.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.83
Moderate
Current Ratio
1.18
Good
Quick Ratio
0.91
Poor
Cash/Share
$3.55
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q1 2026
Revenue
$2.9B
Gross Margin
32.5%
Op. Margin
14.0%
Net Margin
8.7%
Total Assets
$16.7B
Liabilities
$8.9B
Equity
$7.4B
Debt/Equity
1.21x
Operating CF
$0.3B
CapEx
$-0.1B
Free Cash Flow
$0.2B
FCF Yield
59%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-07-21
$N/A
2026-04-21
$2.5
+5.6% surprise
2026-02-10
$2.42
+2.6% surprise
2025-10-21
$2.6
+3.9% surprise
Healthcare Sector Comparison
Comparing DGX against 546 companies in the Healthcare sector
(29 bullish, 162 neutral, 355 bearish)
P/E Ratio
21.69
This Stock
vs
77.79
Sector Avg
-72.1%
(Discount)
Return on Equity (ROE)
14.54%
This Stock
vs
-90.32%
Sector Avg
-116.1%
(Below Avg)
Profit Margin
9.08%
This Stock
vs
-16.47%
Sector Avg
-155.1%
(Weaker)
Debt to Equity
0.83
This Stock
vs
2.72
Sector Avg
-69.6%
(Less Debt)
Revenue Growth
9.2%
This Stock
vs
127.18%
Sector Avg
-92.8%
(Slower)
Current Ratio
1.18
This Stock
vs
4.53
Sector Avg
-74.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
DGX
Quest Diagnostics Incorporated
|
NEUTRAL | $21.73B | 21.69 | 14.5% | 9.1% | $196.27 | |
|
HUM
Humana Inc.
|
BEARISH | $21.45B | 18.06 | 7.0% | 0.9% | $177.86 | Compare |
|
ROIV
Roivant Sciences Ltd.
|
NEUTRAL | $21.35B | - | -19.1% | -% | $29.83 | Compare |
|
BNTX
BioNTech SE
|
BEARISH | $22.34B | - | -5.9% | -39.6% | $88.88 | Compare |
|
DXCM
DexCom, Inc.
|
BULLISH | $23.29B | 32.26 | 30.6% | 16.0% | $58.06 | Compare |
DGX
Quest...
NEUTRAL
Mkt Cap
$21.7B
P/E
21.7
ROE
14.5%
Price
$196.27
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-09 | WENTWORTH TIMOTHY CHARLES | Director | Stock Award | 215 | - |
| 2026-03-05 | DOHERTY CATHERINE T | Officer | Sale | 5,558 | $1,146,115 |
| 2026-03-05 | PREVOZNIK MICHAEL E | General Counsel | Sale | 3,878 | $799,682 |
| 2026-03-05 | PLEWMAN PATRICK | Officer | Sale | 2,855 | $588,730 |
| 2026-03-04 | DOHERTY CATHERINE T | Officer | Stock Award | 11,364 | $2,328,029 |
| 2026-03-04 | SAMAD SAMER ABDUL | Chief Financial Officer | Stock Award | 13,947 | $2,857,182 |
| 2026-03-04 | DEPPE MICHAEL J | Officer | Stock Award | 1,473 | $301,759 |
| 2026-03-04 | KUPPUSAMY KARTHIK | Officer | Stock Award | 6,200 | $1,270,132 |
| 2026-03-04 | KUPPUSAMY KARTHIK | Officer | Sale | 2,628 | $538,372 |
| 2026-03-04 | DELANEY MARK E | Officer | Stock Award | 5,682 | $1,164,015 |
| 2026-03-04 | PREVOZNIK MICHAEL E | General Counsel | Stock Award | 7,232 | $1,481,548 |
| 2026-03-04 | DAVIS J E CAUSEY | Chief Executive Officer | Stock Award | 51,652 | $10,581,429 |
| 2026-03-04 | PLEWMAN PATRICK | Officer | Stock Award | 5,682 | $1,164,015 |
| 2026-03-03 | DOHERTY CATHERINE T | Officer | Sale | 632 | $131,285 |
| 2026-03-03 | PREVOZNIK MICHAEL E | General Counsel | Sale | 526 | $109,266 |
WENTWORTH TIMOTHY CHARLES
Director
2026-03-09
215 shares
DOHERTY CATHERINE T
Officer
2026-03-05
5,558 shares
·
$1,146,115
PREVOZNIK MICHAEL E
General Counsel
2026-03-05
3,878 shares
·
$799,682
PLEWMAN PATRICK
Officer
2026-03-05
2,855 shares
·
$588,730
DOHERTY CATHERINE T
Officer
2026-03-04
11,364 shares
·
$2,328,029
SAMAD SAMER ABDUL
Chief Financial Officer
2026-03-04
13,947 shares
·
$2,857,182
DEPPE MICHAEL J
Officer
2026-03-04
1,473 shares
·
$301,759
KUPPUSAMY KARTHIK
Officer
2026-03-04
6,200 shares
·
$1,270,132
KUPPUSAMY KARTHIK
Officer
2026-03-04
2,628 shares
·
$538,372
DELANEY MARK E
Officer
2026-03-04
5,682 shares
·
$1,164,015
PREVOZNIK MICHAEL E
General Counsel
2026-03-04
7,232 shares
·
$1,481,548
DAVIS J E CAUSEY
Chief Executive Officer
2026-03-04
51,652 shares
·
$10,581,429
PLEWMAN PATRICK
Officer
2026-03-04
5,682 shares
·
$1,164,015
DOHERTY CATHERINE T
Officer
2026-03-03
632 shares
·
$131,285
PREVOZNIK MICHAEL E
General Counsel
2026-03-03
526 shares
·
$109,266
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
10-Q
8-K
DEF 14A
10-K
DGX operates within the clinical testing industry, as detailed in its 10-K filing dated February 26, 2026. While specific financial metrics were not provided in the excerpts, the filing includes comprehensive sections regarding management's discussion of financial conditions and various risk factors.
8-K
8-K
10-Q
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
16 analysts
UBS
2026-04-22
Neutral
Neutral
Baird
2026-04-22
Neutral
Neutral
Barclays
2026-04-22
Overweight
Overweight
Truist Securities
2026-04-22
Hold
Hold
Evercore ISI Group
2026-04-08
In-Line
In-Line
Mizuho
2026-02-12
Outperform
Outperform
Truist Securities
2026-02-11
Hold
Hold
UBS
2026-02-11
Neutral
Neutral
Evercore ISI Group
2026-02-11
In-Line
In-Line
Barclays
2026-02-11
Overweight
Overweight
Past News Coverage
Recent headlines mentioning DGX from our newsroom.
Newest → oldest
No matching news yet.